- Home
- BSM vs SLS Comparison
BSM vs SLS Comparison
Compare BSM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSM | SLS |
|---|---|---|
| Founded | 1876 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2015 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BSM | SLS |
|---|---|---|
| Price | $14.86 | $11.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $10.00 |
| AVG Volume (30 Days) | 359.4K | ★ 7.0M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.40% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $469,919,000.00 | N/A |
| Revenue This Year | $11.03 | N/A |
| Revenue Next Year | $9.63 | $110.98 |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | ★ 8.35 | N/A |
| 52 Week Low | $12.32 | $1.39 |
| 52 Week High | $15.49 | $15.88 |
Technical Indicators
Market Signals| Indicator | BSM | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 39.35 |
| Support Level | $14.53 | $10.85 |
| Resistance Level | $15.20 | $15.77 |
| Average True Range (ATR) | 0.24 | 0.91 |
| MACD | -0.02 | -0.36 |
| Stochastic Oscillator | 53.62 | 9.33 |
Price Performance
Historical ComparisonAbout BSM Black Stone Minerals L.P.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.